Re: Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.
Publication
, Journal Article
Assimos, DG
Published in: J Urol
November 2020
Duke Scholars
Published In
J Urol
DOI
EISSN
1527-3792
Publication Date
November 2020
Volume
204
Issue
5
Start / End Page
1090 / 1091
Location
United States
Related Subject Headings
- Urology & Nephrology
- Tolvaptan
- Polycystic Kidney, Autosomal Dominant
- Humans
- Benzazepines
- Antidiuretic Hormone Receptor Antagonists
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Assimos, D. G. (2020). Re: Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan. J Urol, 204(5), 1090–1091. https://doi.org/10.1097/JU.0000000000001258.01
Assimos, Dean G. “Re: Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.” J Urol 204, no. 5 (November 2020): 1090–91. https://doi.org/10.1097/JU.0000000000001258.01.
Assimos DG. Re: Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan. J Urol. 2020 Nov;204(5):1090–1.
Assimos, Dean G. “Re: Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.” J Urol, vol. 204, no. 5, Nov. 2020, pp. 1090–91. Pubmed, doi:10.1097/JU.0000000000001258.01.
Assimos DG. Re: Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan. J Urol. 2020 Nov;204(5):1090–1091.
Published In
J Urol
DOI
EISSN
1527-3792
Publication Date
November 2020
Volume
204
Issue
5
Start / End Page
1090 / 1091
Location
United States
Related Subject Headings
- Urology & Nephrology
- Tolvaptan
- Polycystic Kidney, Autosomal Dominant
- Humans
- Benzazepines
- Antidiuretic Hormone Receptor Antagonists
- 3202 Clinical sciences
- 1103 Clinical Sciences